Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates

Summary

The purpose of the study is to evaluate the efficacy and safety of Cadisurf (goat lung surfactant extract) as compared to Survanta (beractant) in the treatment of respiratory distress syndrome in preterm neonates (with gestation of 26 to 32 weeks).

Timeline

Start

2016-06

Primary completion

2019-02

Completion

2019-05

Publications

• Jain K, Nangia S, Ballambattu VB, Sundaram V, Sankar MJ, Ramji S, Vishnubhatla S, Thukral A, Gupta YK, Plakkal N, Sundaram M, Jajoo M, Kumar P, Jayaraman K, Jain A, Saili A, Murugesan A, Chawla D, Murki S, Nanavati R, Rao S, Vaidya U, Mehta A, Arora K, Mondkar J, Arya S, Bahl M, Utture A, Manerkar S, Bhat SR, Parikh T, Kumar M, Bajpai A, Sivanandan S, Dhawan PK, Vishwakarma G, Bangera S, Kumar S, Gopalakrishnan S, Jindal A, Natarajan CK, Saini A, Karunanidhi S, Malik M, Narang P, Kaur G, Yadav CP, Deorari A, Paul VK, Agarwal R. Goat lung surfactant for treatment of respiratory distress syndrome among preterm neonates: a multi-site randomized non-inferiority trial. J Perinatol. 2019 Sep;39(Suppl 1):3-12. doi: 10.1038/s41372-019-0472-0.

Drugs

Indications